A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.

@article{Evens2013API,
  title={A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.},
  author={Andrew M Evens and Steven T. Rosen and Irene B Helenowski and Justin P. Kline and Annette H\ojmann Larsen and Jennifer Colvin and Jane N. Winter and Koen M. van Besien and Leo I Gordon and Sonali M Smith},
  journal={British journal of haematology},
  year={2013},
  volume={163 1},
  pages={55-61}
}
There remains an unmet therapeutic need for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL). We conducted a phase I/II trial with bortezomib (dose-escalated to 1·6 mg/m(2) ) given concurrently with gemcitabine (800 mg/m(2) ) days 1 + 8 q21 d. Of 32 patients, 16 each had relapsed/refractory PTCL and DLBCL. Median prior therapies were 3 and 35% had failed transplant. Among the first 18 patients, 67% experienced grade 3/4 neutropenia… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Treatment of Peripheral T-Cell Lymphoma in Community Settings.

Clinical lymphoma, myeloma & leukemia • 2017
View 5 Excerpts
Highly Influenced

Therapeutic options in peripheral T cell lymphoma

Journal of hematology & oncology • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…